September 2, 2015 8:16 PM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
MediciNova, Inc. (NASDAQ: MNOV) today announced that the first advanced ALS patient, using non-invasive ventilation (NIV), has enrolled in the Phase 2 clinical trial evaluating MN-166 (ibudilast) in both early and advanced stage ALS. MediciNova amended the protocol to expand its recruitment to include advanced ALS patients in the trial, and this amendment was approved by FDA (U.S. Food and Drug Administration). The amended protocol now plans enrollment of 60 advanced ALS patients with NIV support in the study in addition to 60 patients without NIV support. Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, is the Principal Investigator of the study. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased to have successfully completed the FDA review period, which allows us to enroll the first advanced ALS patient with NIV support. The safety and efficacy data from advanced ALS patients will be important for our development efforts in ALS and is complementary to the ongoing study that is enrolling ALS
See full press release
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.